Nationwide Access to Ultrafiltration Therapy Possible with Nuwellis and Premier, Inc. Collaboration
Aquadex® is the first and only therapy currently available in this newly-established Aquapheresis product category. The collaboration provides
“Premier is a trusted healthcare leader, and working with them to expand access to ultrafiltration with Aquadex is a significant milestone for the Company and the customers we serve,” said
Premier, Inc. is a leading healthcare improvement company, uniting an alliance of more than 4,100
The agreement was included in the expedited approval program instituted by Premier to quickly offer COVID-19 innovations to patients.
About the Aquadex SmartFlow System
The Aquadex SmartFlow® System delivers clinically proven therapy using a simple, flexible and smart method of removing excess fluid from patients suffering from hypervolemia (fluid overload). The Aquadex SmartFlow System is indicated for temporary (up to 8 hours) or extended (longer than 8 hours in patients who require hospitalization) use in adult and pediatric patients weighing 20 kg or more whose fluid overload is unresponsive to medical management, including diuretics. All treatments must be administered by a health care provider, within an outpatient or inpatient clinical setting, under physician prescription, both having received training in extracorporeal therapies.
Certain statements in this release may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, statements regarding the new market opportunities and anticipated growth in 2021 and beyond. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risks associated with our ability to execute on our commercialization strategy, the impact of the COVID-19 pandemic, the possibility that we may be unable to raise sufficient funds necessary for our anticipated operations, our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and other risks and uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the date when made. Nuwellis does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Nestor JaramilloPresident, Chief Executive Officer and Chief Financial Officer, Nuwellis, Inc.firstname.lastname@example.org Matt Basco, CFA Gilmartin Group LLCMatt.email@example.com MEDIA: Jessica StebingHealth+Commerce firstname.lastname@example.org
Source: Nuwellis, Inc.